Neuropace Inc (NPCE NASDAQ) stock market data APIs
$13.1566
0.06(0.5%)
as of May 30, 2025
Try our APIs with
free plan!
Neuropace Inc Financial Data Overview
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Prev. Close
13.1566
Open
13.217
High
13.3659
Low
12.6328
52 wk Range
5.45-18.975
Market Cap
434 M
Shares Outstanding
32 799 K
Revenue
84 306 K
EPS
-0.18
Beta
2.051
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Neuropace Inc data using free add-ons & libraries
Get Neuropace Inc Fundamental Data
Neuropace Inc Fundamental data includes:
- Net Revenue: 84 306 K
- EBITDA: -19 062 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-03-03
- EPS/Forecast: -0.2233
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Neuropace Inc News
New
H.C. Wainwright Initiates Coverage of NeuroPace (NPCE) With Buy Rating
On May 28, H.C. Wainwright analyst Yi Chen initiated coverage of NeuroPace, Inc. (NASDAQ:NPCE) with a Buy rating and a price target of $18. The rating comes after the company released preliminary resu...
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of NeuroPace, Inc. - NPCE
NEW YORK, May 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of NeuroPace, Inc. (“NeuroPace” or the “Company”) (NASDAQ: NPCE). Such investors ...
NPCE Stock Tumbles Despite Positive One-Year Data From NAUTILUS Trial
NeuroPace NPCE recently announced promising preliminary one-year results from its pivotal NAUTILUS trial, evaluating the RNS System in patients with idiopathic generalized epilepsy (IGE). This study m...
NeuroPace Announces Preliminary Results from One-Year Data in NAUTILUS Study
-- NeuroPace has completed the primary endpoint analysis of the one-year data from the first and only clinical study to evaluate neuromodulation therapy for idiopathic generalized epilepsy -- Study m...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
